Document Detail

Long-term treatment of anemia with recombinant human erythropoietin in familial amyloidosis TTR V30M.
MedLine Citation:
PMID:  18925459     Owner:  NLM     Status:  MEDLINE    
Familial amyloidosis or familial amyloid polyneuropathy (FAP) TTR V30M is a hereditary disease presented, in most cases, as a sensorimotor and autonomic neuropathy. Normocytic and normochromic anaemia was found in 24.8% of symptomatic FAP patients associated to lower serum erythropoietin (Epo) levels. Erythropoietin has been reported as efficient in anaemia correction in this disease. To evaluate the tolerance and efficacy of this treatment, a retrospective longitudinal study with 24 patients was undertaken. Patients were followed for at least 6 months. Haemoglobin, hematocrit, iron status, serum creatinine and urea and r-HuEPO doses were monitored, at 0, 3 months, 6 months and at the end of the follow-up. Long-term use of r-HuEPO proved to be efficient in the treatment of anaemia in familial amyloidosis TTR V30M and, despite the disease progression, no resistance cases to this treatment were observed. Positive side effects, like improvement on orthostatic hypotension symptoms and well-being sensation, contributing to confirm erythropoietin as a drug of choice to treat anaemia in amyloidosis TTR V30M.
Idalina Beirão; Luísa Lobato; Luciana Moreira; Paulo Mp Costa; Isabel Fonseca; António Cabrita; Graça Porto
Related Documents :
22588699 - Validation of an ultrasound-guided technique to establish a liver-to-coelom ratio and a...
10504379 - Postoperative peritonitis originating from the duodenum: operative management by intuba...
22424349 - Diagnosis and management of hydatid liver disease in children: a report of 156 patients...
8320949 - Does anemia correction by rhuepo improve uremic cardiopathy?
19506469 - Outcomes of vascular access creation prior to dialysis: building the case for early ref...
17984429 - The use of nocturnal home hemodialysis as salvage therapy for patients experiencing per...
23248829 - Comparison of fascia iliaca compartment block and 3-in-1 block in adults undergoing kne...
3489719 - Is the outcome of coronary artery bypass graft surgery predictable in patients with sev...
24184649 - Orthosis versus no orthosis for the treatment of thoracolumbar burst fractures without ...
Publication Detail:
Type:  Letter    
Journal Detail:
Title:  Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis     Volume:  15     ISSN:  1744-2818     ISO Abbreviation:  Amyloid     Publication Date:  2008 Sep 
Date Detail:
Created Date:  2008-10-17     Completed Date:  2008-11-18     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9433802     Medline TA:  Amyloid     Country:  United States    
Other Details:
Languages:  eng     Pagination:  205-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amyloidosis, Familial / complications*,  epidemiology,  genetics
Anemia / complications,  epidemiology,  therapy*
Blood Pressure
Erythropoietin, Recombinant / therapeutic use*
Follow-Up Studies
Hemoglobins / analysis
Middle Aged
Mutation / genetics*
Prealbumin / genetics*
Time Factors
Treatment Outcome
Reg. No./Substance:
0/Erythropoietin, Recombinant; 0/Hemoglobins; 0/Prealbumin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Late enhancement in cardiac amyloidosis: correlation of MRI enhancement pattern with histopathologic...
Next Document:  Bullous lesions of the vulvar region revealing both AL amyloidosis and vulvar carcinoma.